Lexicon Pharmaceuticals, Inc. announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors. She was chief commercial officer of The Medicines Company until its acquisition by Novartis, and subsequently served as chief commercial officer at DalCorp Pharmaceuticals.

Prior to her time at The Medicines Company, Ms. Sullivan held senior positions at AstraZeneca, Pfizer, Wyeth, and GlaxoSmithKline in a variety of disciplines, including market access, strategy, marketing, brand management, business development and integration. Ms. Sullivan served as a director of OrthogenRx, a privately held medical device company, until it was acquired by Avanos Medical in January 2022 and currently serves as a director of Amarin. Ms. Sullivan received her B.A. from Dickinson College.

Ms. Sullivan?s appointment is concurrent with the resignation from the Lexicon Board of Directors of Frank Palantoni after 18 years of service culminating in the approval of INPEFA.